This study will follow participants who completed the TED-C14-006 study. The purpose of this study is to evaluate the long-term safety and efficacy of teduglutide in pediatric participants with Short Bowel Syndrome (SBS). This study will also offer teduglutide treatment to eligible participants, regardless of treatment received in TED-C14-006 or SHP633-301.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Timeframe: From start of study drug administration up to follow-up (up to 46 months)
Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment
Timeframe: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
Change From Baseline in Average Total Urine Output at Last Visit During Non-Teduglutide Treatment (NT)
Timeframe: Baseline, Last visit in NT (up to Month 39)
Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment
Timeframe: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
Change From Baseline in Average Number of Stools Per Day at Last Visit During Non-Teduglutide Treatment (NT)
Timeframe: Baseline, Last visit in NT (up to Month 39)
Change From Baseline in Average Total Daily Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment
Timeframe: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
Change From Baseline in Average Total Daily Stool/Mixed Stool Diaper Weight at Last Visit During Non-Teduglutide Treatment (NT)
Timeframe: Baseline, Last visit in NT (up to Month 39)
Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment
Timeframe: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
Change From Baseline in Average Total Ostomy Output at Last Visit During Non-Teduglutide Treatment (NT)
Timeframe: Baseline, Last visit in NT (up to Month 39)
Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment
Timeframe: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
Change From Baseline in Average Bristol Stool Form Score at Last Visit During Non-Teduglutide Treatment (NT)
Timeframe: Baseline, Last visit in NT (up to Month 39)
Number of Participants With Positive Specific Antibodies at End of Study (EOS)
Timeframe: At EOS (up to 46 months)
Change From Baseline in Body Weight Z-score at EOT of Last Cycle During Teduglutide Treatment
Timeframe: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
Change From Baseline in Body Weight Z-score at Last Visit During Non-Teduglutide Treatment (NT)
Timeframe: Baseline, Last visit in NT (up to Month 39)
Change From Baseline in Height Z-score at EOT of Last Cycle During Teduglutide Treatment
Timeframe: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
Change From Baseline in Height Z-score at Last Visit During Non-Teduglutide Treatment
Timeframe: Baseline, Last visit in NT (up to Month 39)
Change From Baseline in Head Circumference Z-score at EOT of Last Cycle During Teduglutide Treatment
Timeframe: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
Change From Baseline in Head Circumference Z-score at Last Visit During Non-Teduglutide Treatment (NT)
Timeframe: Baseline, Last visit in NT (up to Month 39)
Change From Baseline in Body Mass Index (BMI) Z-score at EOT of Last Cycle During Teduglutide Treatment
Timeframe: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
Change From Baseline in Body Mass Index (BMI) Z-score at Last Visit During Non-Teduglutide Treatment (NT)
Timeframe: Baseline, Last visit in NT (up to Month 39)